查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1822388

2032 年登革热疫苗市场预测：按产品、疫苗类型、佐剂、给药途径、分销管道、最终用户和地区进行的全球分析

Dengue Vaccine Market Forecasts to 2032 - Global Analysis By Product (Dengvaxia, Qdenga, and Other Pipeline Candidates), Vaccine Type, Treatment Adjuncts, Route of Administration, Distribution Channel, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球登革热疫苗市场预计在 2025 年达到 4.8961 亿美元，到 2032 年将达到 13.5891 亿美元，预测期内复合年增长率为 15.7%。

登革热疫苗是预防登革热（一种蚊媒病毒性疾病）的处方免疫接种。疫苗能够引发免疫反应，使人体产生保护性抗体，进而抵抗登革热病毒。这些疫苗的主要目的是最大限度地降低感染风险，减轻病情严重程度，并避免住院。这些疫苗在疫情控制中发挥重要作用，尤其是在登革热构成重大健康挑战的登革热流行地区。

公众健康意识不断增强

各国政府和非政府组织正在加强登革热预防教育工作，尤其是在登革热流行地区。数位平台和行动医疗应用程式正被用于传播疫苗讯息和追踪疫苗接种覆盖率。随着都市化和气候变迁扩大蚊子栖息地，预防​​措施变得更加迫切。监测和诊断领域的技术创新使得早期发现和有针对性的疫苗接种策略成为可能。这种意识的提高正在推动对可靠且可及的登革热疫苗的需求，以满足不同人群的需求。

安全性和有效性问题

由于担心疫苗安全性以及不同血清型疫苗疗效的差异，疫苗在某些地区的推广速度有所放缓。监管机构呼吁进行大规模临床试验，以检验疫苗的长期疗效，尤其是儿童和老年族群。四种登革热病毒株的复杂性对免疫抗原性一致性提出了挑战。不利事件监测系统正在升级，以确保上市后监测和透明度。人工智慧临床分析等新技术正在帮助完善疗效模型，但公众的怀疑仍然是一个障碍。这些因素导致一些国家采取谨慎的推广策略，市场渗透速度缓慢。

下一代疫苗的开发

mRNA平台和重组DNA技术的进步使得免疫反应更具针对性和持久性。研究机构和生物技术公司正在合作开发适用于热带气候的耐热製剂。人工智慧和生物资讯学正在加速抗原设计和测试模拟，缩短开发时间。各国政府正在提供津贴和加速核准，以支持该领域的创新。随着全球卫生重点转向疫情防范，登革热疫苗研发正获得策略性发展动能。

经济限制

负担能力仍然是一个重大障碍，尤其是在低收入和高负担地区。有限的医疗预算和相互竞争的优先事项往往会延迟疫苗的采购和分配。登革热疫苗等复杂生技药品的高昂製造成本影响了定价策略。供应链效率低和低温运输需求进一步加剧了偏远地区的物流。模组化和分散式製造的新兴趋势旨在降低成本并改善可及性。如果没有持续的资金筹措和国际支持，市场扩张可能会不均衡，并且容易受到经济衝击的影响。

COVID-19的影响

疫情扰乱了疫苗临床试验，并转移了登革热疫苗接种计画的资源。封锁和旅行限制推迟了现场测试和监管审查，从而推迟了产品上市。然而，新冠疫情加速了数位医疗的普及，包括远端试验监控和基于人工智慧的数据收集。疫情期间建立的紧急使用框架目前正在适应登革热疫苗的核准。后疫情时代策略强调韧性供应链和综合疾病监测系统，其中将登革热作为优先事项。

预测期内，登革热疫苗市场预计将成为最大的市场

由于监管部门的核准和完善的全球分销网络，预计登革热疫苗市场将在预测期内占据最大市场份额。登革热疫苗是唯一获得广泛许可的疫苗，已在多个国家（主要在亚洲和拉丁美洲）投入使用。正在进行的上市后研究正在改善其风险-效益状况，尤其对于血清阳性族群。低温运输物流和数位追踪技术的进步正在提高疫苗的可用性和可靠性。与公共卫生机构的伙伴关係正在扩大登革热疫苗在学校免疫接种计画中的覆盖率。儘管过去存在争议，但Dengvaxia强大的市场影响力和基础设施支撑了其市场领先地位。

预测期内肠外药物市场将以最高复合年增长率成长

预计在预测期内，肠外疫苗领域将达到最高成长率。注射剂可精准给药，并融入现有的医疗保健工作流程。无针注射器和微阵列贴片等创新技术正在提高患者依从性并缩短给药时间。低温运输优化和智慧包装技术使疫苗肠外给药在偏远地区更可行。由于下一代登革热候选疫苗的吸收特性稳定，临床试验越来越倾向肠外给药。随着医疗保健系统的现代化，肠外给药正成为大规模疫苗接种的首选途径。

比最大的地区

预计亚太地区将在预测期内占据最大的市场份额。印度、印尼和菲律宾等国家正在透过政府资助的宣传活动扩大疫苗接种计画。对生物技术基础设施和本地製造业的投资正在减少对进口的依赖。行动医疗平台和人工智慧驱动的疾病地图绘製正在提高疫苗部署的效率。全球製药公司与区域参与者之间的策略联盟正在加速技术转移和监管协调。

复合年增长率最高的地区：

在预测期内，北美预计将凭藉其尖端研发和积极的监管支持，实现最高的复合年增长率。美国和加拿大正在大力投资疫苗创新，包括基于mRNA的登革热候选疫苗。人工智慧和机器学习正在整合到临床试验设计和即时疗效监测中。监管机构正在简化热带疾病疫苗的核准途径，以加快疫苗的上市速度。官民合作关係正在资助与全球扩张一致的先进生产和分销模式。随着气候变迁导緻美国南部登革热风险增加，北美正逐渐成为关键的成长前线。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球登革热疫苗市场（按产品）

  • 登革热疫苗
  • 库登加
  • 其他产品

6. 全球登革热疫苗市场（依疫苗类型）

  • 减毒活疫苗
  • DNA疫苗
  • 嵌合体减毒活疫苗
  • 核酸疫苗
  • 灭活疫苗
  • 次单元/VLP疫苗

7. 全球登革热疫苗市场（按辅助治疗剂）

  • 利尿剂
  • 抗过敏药物
  • 支持性护理
  • 抗凝血剂

8. 全球登革热疫苗市场（依给药途径）

  • 口服
  • 肠外

9. 全球登革热疫苗市场（依分销管道）

  • 公共疫苗接种计划
  • 医院药房
  • 私人诊所和医院
  • 旅行诊所
  • 零售药局
  • 网路药局

10. 全球登革热疫苗市场（依最终用户）

  • 儿童（9至16岁）
  • 成人（17岁以上）
  • 居家照护环境
  • 旅行者和军事人员
  • 政府和公共卫生机构
  • 医院和专科诊所
  • 其他最终用户

11. 全球登革热疫苗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • Sanofi
  • Medigen Vaccine Biologics Corp.
  • Takeda Pharmaceutical Company
  • Biological E. Limited
  • GlaxoSmithKline（GSK）
  • Serum Institute of India
  • Bharat Biotech
  • Vabiotech
  • Merck & Co.
  • Panacea Biotec
  • F. Hoffmann-La Roche Ltd.
  • BioNet-Asia Co. Ltd.
  • Novartis AG
  • Instituto Butantan
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC31142

According to Stratistics MRC, the Global Dengue Vaccine Market is accounted for $489.61 million in 2025 and is expected to reach $1358.91 million by 2032 growing at a CAGR of 15.7% during the forecast period. A dengue vaccine is a preventive immunization formulated to safeguard people from dengue fever, a viral illness transmitted by mosquitoes. By triggering an immune response, it enables the body to generate protective antibodies that help defend against the dengue virus. Its primary purpose is to minimize infection risks, reduce disease intensity, and prevent hospitalizations. This vaccine plays a vital role in controlling outbreaks, especially in dengue-endemic areas where the disease poses significant health challenges.

Market Dynamics:

Driver:

Growing public health awareness

Governments and NGOs are intensifying education efforts around dengue prevention, especially in endemic regions. Digital platforms and mobile health apps are being leveraged to disseminate vaccine information and track immunization coverage. As urbanization and climate change expand mosquito habitats, the urgency for preventive measures is rising. Technological innovations in surveillance and diagnostics are enabling earlier detection and targeted vaccination strategies. This growing consciousness is fostering demand for reliable and accessible dengue vaccines across diverse populations.

Restraint:

Safety and efficacy concerns

Concerns over vaccine safety and variable efficacy across serotypes are slowing adoption in certain regions. Regulatory bodies require extensive clinical trials to validate long-term outcomes, especially for pediatric and elderly populations. The complexity of dengue's four viral strains poses challenges for consistent immunogenicity. Adverse event monitoring systems are being upgraded to ensure post-marketing surveillance and transparency. Emerging technologies like AI-driven trial analytics are helping refine efficacy models, but public skepticism remains a hurdle. These factors contribute to cautious rollout strategies and delayed market penetration in some countries.

Opportunity:

Development of next-generation vaccines

Advances in mRNA platforms and recombinant technologies are enabling more targeted and durable immune responses. Research institutions and biotech firms are collaborating on thermostable formulations suitable for tropical climates. AI and bioinformatics are accelerating antigen design and trial simulations, reducing development timelines. Governments are offering grants and fast-track approvals to support innovation in this space. As global health priorities shift toward pandemic preparedness, dengue vaccine R&D is gaining strategic momentum.

Threat:

Economic constraints

Affordability remains a major barrier, particularly in low-income and high-burden regions. Limited healthcare budgets and competing priorities often delay vaccine procurement and distribution. Manufacturing costs for complex biologics like dengue vaccines are high, impacting pricing strategies. Supply chain inefficiencies and cold chain requirements further strain logistics in remote areas. Emerging trends in modular production and decentralized manufacturing aim to reduce overheads and improve access. Without sustained funding and international support, market expansion may be uneven and vulnerable to economic shocks.

Covid-19 Impact

The pandemic disrupted vaccine trials and diverted resources away from dengue immunization programs. Lockdowns and travel restrictions delayed field studies and regulatory reviews, slowing product launches. However, Covid-19 accelerated digital health adoption, including remote trial monitoring and AI-based data collection. Emergency use frameworks introduced during the pandemic are now being adapted for dengue vaccine approvals. Post-Covid strategies emphasize resilient supply chains and integrated disease surveillance systems that include dengue as a priority.

The dengvaxia segment is expected to be the largest during the forecast period

The dengvaxia segment is expected to account for the largest market share during the forecast period, due to its established regulatory approvals and global distribution footprint. It remains the only widely licensed dengue vaccine with multi-country deployment, especially in Asia and Latin America. Continuous post-marketing studies are refining its risk-benefit profile, particularly for seropositive individuals. Technological upgrades in cold chain logistics and digital tracking are enhancing its reach and reliability. Partnerships with public health agencies are expanding its coverage in school-based immunization programs. Despite past controversies, Dengvaxia's entrenched presence and infrastructure support its leading market position.

The parenteral segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the parenteral segment is predicted to witness the highest growth rate, driven by their proven delivery efficiency and immunogenicity. Injectable formats offer precise dosing and are compatible with existing healthcare workflows. Innovations in needle-free injectors and microarray patches are improving patient compliance and reducing administration time. Cold chain optimization and smart packaging technologies are making parenteral vaccines more viable in remote settings. Clinical trials are increasingly favoring parenteral delivery for next-gen dengue candidates due to consistent absorption profiles. As healthcare systems modernize, parenteral formats are becoming the preferred choice for mass immunization drives.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share propelled by high disease prevalence and robust public health initiatives. Countries like India, Indonesia, and the Philippines are scaling up vaccination programs through government-backed campaigns. Investments in biotech infrastructure and local manufacturing are reducing dependency on imports. Mobile health platforms and AI-driven disease mapping are enhancing vaccine deployment efficiency. Strategic collaborations between global pharma firms and regional players are accelerating technology transfer and regulatory harmonization.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by cutting-edge R&D and proactive regulatory support. The U.S. and Canada are investing heavily in vaccine innovation, including mRNA-based dengue candidates. AI and machine learning are being integrated into clinical trial design and real-time efficacy monitoring. Regulatory agencies are streamlining approval pathways for tropical disease vaccines, encouraging faster market entry. Public-private partnerships are funding advanced manufacturing and distribution models tailored for global deployment. As climate change increases dengue risk in southern U.S. regions, North America is emerging as a key growth frontier.

Key players in the market

Some of the key players profiled in the Dengue Vaccine Market include Sanofi, Medigen Vaccine Biologics Corp., Takeda Pharmaceutical Company, Biological E. Limited, GlaxoSmithKline (GSK), Serum Institute of India, Bharat Biotech, Vabiotech, Merck & Co., Panacea Biotec, F. Hoffmann-La Roche Ltd., BioNet-Asia Co. Ltd., Novartis AG, Instituto Butantan, and Teva Pharmaceutical Industries Ltd.

Key Developments:

In Sepetember 2025, Medigen Vaccine Biologics Corp (MVC) has signed a regional distribution agreement with the pharmaceutical company Substipharm Biologics to expand the market reach of enterovirus vaccine products in Southeast Asia. The two companies have finalized an exclusive distribution agreement for ENVACGEN(R) Enterovirus A71 (EV-A71) vaccine in Vietnam as the first country of launch.

In August 2025, Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc.. This acquisition strengthens Sanofi's early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer's disease. In addition, the acquisition of Vigil's preclinical pipeline will further strengthen Sanofi's research in various neurodegenerative diseases.

Products Covered:

  • Dengvaxia
  • Qdenga
  • Other Pipeline Candidates

Vaccine Types Covered:

  • Live Attenuated Vaccine
  • DNA Vaccine
  • Chimeric Live Attenuated Vaccine
  • Nucleic Acid-Based Vaccine
  • Inactivated Vaccine
  • Subunit/VLP Vaccine

Treatment Adjuncts Covered:

  • Diuretics
  • Anti-Allergic Agents
  • Supportive Therapies
  • Blood Thinners

Route of Administrations Covered:

  • Oral
  • Parenteral

Distribution Channels Covered:

  • Public Immunization Programs
  • Hospital Pharmacy
  • Private Clinics & Hospitals
  • Travel Clinics
  • Retail Pharmacy
  • Online Pharmacy

End Users Covered:

  • Pediatrics (9-16 years)
  • Adults (>=17 years)
  • Homecare Settings
  • Travelers & Military Personnel
  • Government & Public Health Agencies
  • Hospitals & Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dengue Vaccine Market, By Product

  • 5.1 Introduction
  • 5.2 Dengvaxia
  • 5.3 Qdenga
  • 5.4 Other Pipeline Candidates

6 Global Dengue Vaccine Market, By Vaccine Type

  • 6.1 Introduction
  • 6.2 Live Attenuated Vaccine
  • 6.3 DNA Vaccine
  • 6.4 Chimeric Live Attenuated Vaccine
  • 6.5 Nucleic Acid-Based Vaccine
  • 6.6 Inactivated Vaccine
  • 6.7 Subunit/VLP Vaccine

7 Global Dengue Vaccine Market, By Treatment Adjuncts

  • 7.1 Introduction
  • 7.2 Diuretics
  • 7.3 Anti-Allergic Agents
  • 7.4 Supportive Therapies
  • 7.5 Blood Thinners

8 Global Dengue Vaccine Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parenteral

9 Global Dengue Vaccine Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Public Immunization Programs
  • 9.3 Hospital Pharmacy
  • 9.4 Private Clinics & Hospitals
  • 9.5 Travel Clinics
  • 9.6 Retail Pharmacy
  • 9.7 Online Pharmacy

10 Global Dengue Vaccine Market, By End User

  • 10.1 Introduction
  • 10.2 Pediatrics (9-16 years)
  • 10.3 Adults (>=17 years)
  • 10.4 Homecare Settings
  • 10.5 Travelers & Military Personnel
  • 10.6 Government & Public Health Agencies
  • 10.7 Hospitals & Specialty Clinics
  • 10.8 Other End Users

11 Global Dengue Vaccine Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Sanofi
  • 13.2 Medigen Vaccine Biologics Corp.
  • 13.3 Takeda Pharmaceutical Company
  • 13.4 Biological E. Limited
  • 13.5 GlaxoSmithKline (GSK)
  • 13.6 Serum Institute of India
  • 13.7 Bharat Biotech
  • 13.8 Vabiotech
  • 13.9 Merck & Co.
  • 13.10 Panacea Biotec
  • 13.11 F. Hoffmann-La Roche Ltd.
  • 13.12 BioNet-Asia Co. Ltd.
  • 13.13 Novartis AG
  • 13.14 Instituto Butantan
  • 13.15 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Dengue Vaccine Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Dengue Vaccine Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Dengue Vaccine Market Outlook, By Dengvaxia (2024-2032) ($MN)
  • Table 4 Global Dengue Vaccine Market Outlook, By Qdenga (2024-2032) ($MN)
  • Table 5 Global Dengue Vaccine Market Outlook, By Other Pipeline Candidates (2024-2032) ($MN)
  • Table 6 Global Dengue Vaccine Market Outlook, By Vaccine Type (2024-2032) ($MN)
  • Table 7 Global Dengue Vaccine Market Outlook, By Live Attenuated Vaccine (2024-2032) ($MN)
  • Table 8 Global Dengue Vaccine Market Outlook, By DNA Vaccine (2024-2032) ($MN)
  • Table 9 Global Dengue Vaccine Market Outlook, By Chimeric Live Attenuated Vaccine (2024-2032) ($MN)
  • Table 10 Global Dengue Vaccine Market Outlook, By Nucleic Acid-Based Vaccine (2024-2032) ($MN)
  • Table 11 Global Dengue Vaccine Market Outlook, By Inactivated Vaccine (2024-2032) ($MN)
  • Table 12 Global Dengue Vaccine Market Outlook, By Subunit/VLP Vaccine (2024-2032) ($MN)
  • Table 13 Global Dengue Vaccine Market Outlook, By Treatment Adjuncts (2024-2032) ($MN)
  • Table 14 Global Dengue Vaccine Market Outlook, By Diuretics (2024-2032) ($MN)
  • Table 15 Global Dengue Vaccine Market Outlook, By Anti-Allergic Agents (2024-2032) ($MN)
  • Table 16 Global Dengue Vaccine Market Outlook, By Supportive Therapies (2024-2032) ($MN)
  • Table 17 Global Dengue Vaccine Market Outlook, By Blood Thinners (2024-2032) ($MN)
  • Table 18 Global Dengue Vaccine Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 19 Global Dengue Vaccine Market Outlook, By Oral (2024-2032) ($MN)
  • Table 20 Global Dengue Vaccine Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 21 Global Dengue Vaccine Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 22 Global Dengue Vaccine Market Outlook, By Public Immunization Programs (2024-2032) ($MN)
  • Table 23 Global Dengue Vaccine Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
  • Table 24 Global Dengue Vaccine Market Outlook, By Private Clinics & Hospitals (2024-2032) ($MN)
  • Table 25 Global Dengue Vaccine Market Outlook, By Travel Clinics (2024-2032) ($MN)
  • Table 26 Global Dengue Vaccine Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
  • Table 27 Global Dengue Vaccine Market Outlook, By Online Pharmacy (2024-2032) ($MN)
  • Table 28 Global Dengue Vaccine Market Outlook, By End User (2024-2032) ($MN)
  • Table 29 Global Dengue Vaccine Market Outlook, By Pediatrics (9-16 years) (2024-2032) ($MN)
  • Table 30 Global Dengue Vaccine Market Outlook, By Adults (>=17 years) (2024-2032) ($MN)
  • Table 31 Global Dengue Vaccine Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 32 Global Dengue Vaccine Market Outlook, By Travelers & Military Personnel (2024-2032) ($MN)
  • Table 33 Global Dengue Vaccine Market Outlook, By Government & Public Health Agencies (2024-2032) ($MN)
  • Table 34 Global Dengue Vaccine Market Outlook, By Hospitals & Specialty Clinics (2024-2032) ($MN)
  • Table 35 Global Dengue Vaccine Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.